Non-competitive immunochemiluminometric assay for cardiotrophin-I detects elevated plasma levels in human heart failure

Cardiotrophin-1 (CT-1) leads to a specific form of ventricular hypertrophy characterized by sarcomeres added in series, and has been reported to be elevated in heart failure. Previous competitive assays for CT-1 necessitate the extraction of plasma and involve prolonged incubations. We describe the development of a non-competitive assay for CT-1 that can measure plasma levels without the need for extraction. Two antibodies specific for the mid-section (amino acids 105‐120) and C-terminal (amino acids 186‐199) portions of CT-1 were developed in rabbits. One antibody was immobilized and used as the capture antibody. The other antibody was anity purified and biotinylated. Unextracted plasma was incubated with these antibodies, and detection was with methylacridinium ester-labelled streptavidin. Plasma was obtained from 40 patients with heart failure and 40 normal control subjects. The non-competitive assay demonstrated a linear increase in chemiluminescence (measured as relative light units) with increasing amounts of full-length recombinant CT-1, with no evidence of a hook eect at high concentrations. The lower limit of detection was 2.9 fmol/ml. Intra-assay coecients of variation ranged from 3.1% to 4.2% in the 10‐40 fmol/well concentration range, and interassay coecients of variation ranged from 3.5% to 4.5% in the 550‐950 fmol/ml range. Measurements of CT-1 levels in patients with heart failure (median 166.5 fmol/ml; range 49.5‐2788 fmol/ml) revealed very significantly elevated levels compared with those in normal controls (median 43.5 fmol/ml; range 11.2‐258.6 fmol/ml; P ! 0.0001 by Mann‐Whitney test). At a CT-1 concentration of 68 fmol/ml, sensitivity and specificity were 95% and 82.5% respectively. Thus this new non-competitive immunochemiluminometric assay for CT-1 could successfully detect full-length recombinant CT-1 in unextracted plasma, and demonstrated that plasma levels of CT-1 were significantly elevated in patients with heart failure.

[1]  S. Sasayama,et al.  Augmented expression of cardiotrophin-1 and its receptor component, gp130, in both left and right ventricles after myocardial infarction in the rat. , 2000, Journal of molecular and cellular cardiology.

[2]  G. Sagnella Measurement and significance of circulating natriuretic peptides in cardiovascular disease. , 1998, Clinical science.

[3]  N. Kennedy,et al.  Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. , 1996, The American journal of cardiology.

[4]  M. Redfield,et al.  Augmented cardiac cardiotrophin-1 in experimental congestive heart failure. , 2000, Circulation.

[5]  B. Brar,et al.  Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli. , 1998, Journal of molecular and cellular cardiology.

[6]  R. T. Lie,et al.  Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. , 1996, Circulation.

[7]  R. A. Hunt,et al.  Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3 : an autocrine loop for hypertrophy. , 2000, Hypertension.

[8]  R. Brown,et al.  Immunoassays using acridinium esters. , 1986, Methods in enzymology.

[9]  W. Wood,et al.  Cardiotrophin-1 , 1995, The Journal of Biological Chemistry.

[10]  I. Kishimoto,et al.  The heart is a source of circulating cardiotrophin-1 in humans. , 2000, Biochemical and biophysical research communications.

[11]  M. Galiñanes,et al.  Cardiotrophin-1 protects the human myocardium from ischemic injury. Comparison with the first and second window of protection by ischemic preconditioning. , 2000, Cardiovascular Research.

[12]  D. Yellon,et al.  Cardiotrophin-1 can protect cardiac myocytes from injury when added both prior to simulated ischaemia and at reoxygenation. , 2001, Cardiovascular research.

[13]  J. Heath,et al.  Cardiotrophin-1 Activates a Distinct Form of Cardiac Muscle Cell Hypertrophy , 1996, The Journal of Biological Chemistry.

[14]  J. Davies,et al.  An immunoluminometric assay for cardiotrophin-1: a newly identified cytokine is present in normal human plasma and is increased in heart failure. , 1999, Biochemical and biophysical research communications.

[15]  K. Chien,et al.  Cardiotrophin 1 (CT-1) Inhibition of Cardiac Myocyte Apoptosis via a Mitogen-activated Protein Kinase-dependent Pathway , 1997, The Journal of Biological Chemistry.